Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

213
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
213
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

664
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
664
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

421
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
421
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

460
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
460
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

211
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
211
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

453
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
453

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ciprofloxacin-Induced Guillain-Barré Syndrome, Posterior Reversible Encephalopathy Syndrome, Hepatotoxicity, and Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Case Report.

Cureus·2026
Same author

Novel epilepsy treatments in clinical development.

Epilepsy & behavior : E&B·2026
Same author

Timing for Starting Antiseizure Medication Withdrawal After Epilepsy Surgery in Adults.

Neurology·2026
Same author

Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.

Epilepsia·2025
Same author

Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort.

Journal of Alzheimer's disease reports·2025
Same author

24-Hour Video EEG in the Evaluation of the Seizure-Free Patient Before Antiseizure Medication Withdrawal.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society·2025

Related Experiment Video

Updated: Jul 18, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K

Drug-resistant epilepsy: Definition, pathophysiology, and management.

Boulenouar Mesraoua1, Francesco Brigo2, Simona Lattanzi3

  • 1Neurosciences Department, Hamad Medical Corporation and Weill Cornell Medical College, Doha, Qatar.

Journal of the Neurological Sciences
|August 19, 2023
PubMed
Summary
This summary is machine-generated.

Drug-resistant epilepsy (DRE) affects one-third of people with epilepsy (PWE) globally. This review defines DRE, explores its biological basis and biomarkers, and proposes management strategies for better seizure control.

Keywords:
Drug resistanceEpilepsySeizureTreatment

More Related Videos

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

12.4K
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

9.0K

Related Experiment Videos

Last Updated: Jul 18, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K
Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

12.4K
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

9.0K

Area of Science:

  • Neurology
  • Clinical Medicine
  • Pharmacology

Background:

  • Epilepsy affects over 51 million people worldwide, with nearly 4.9 million new cases annually.
  • Antiseizure medications (ASMs) are the primary treatment for people with epilepsy (PWE).
  • Approximately one-third of PWE experience drug-resistant epilepsy (DRE), failing to achieve seizure control with ASMs.

Purpose of the Study:

  • To define drug-resistant epilepsy (DRE).
  • To elucidate the biological underpinnings and clinical biomarkers associated with DRE.
  • To propose practical management strategies for DRE.

Main Methods:

  • This study is a narrative review.
  • Literature search on DRE definition, pathophysiology, biomarkers, and treatment.
  • Synthesis of current knowledge and clinical guidelines.

Main Results:

  • Drug-resistant epilepsy (DRE) is characterized by persistent seizures despite adequate trials of two or more ASMs.
  • Biological factors and specific clinical biomarkers contribute to the understanding and potential prediction of DRE.
  • Evidence-based management strategies can improve outcomes for individuals with DRE.

Conclusions:

  • Accurate definition and understanding of DRE are crucial for effective patient care.
  • Identifying biomarkers may aid in early diagnosis and personalized treatment approaches for DRE.
  • Implementing targeted management strategies is essential to improve seizure control and quality of life for PWE with DRE.